Clinical trial · Observational
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
NCT07508319CI-TRIAL-00107195recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head & Neck Cancer | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- differences in TILs counts
- timeFrame
- 2 years
- description
- detection of differences in TILs counts from Laryngeal dysplasia to progression to carcinoma
Secondary outcomes (1)
- measure
- Differences in TILs counts in LDy lesions
- timeFrame
- 2 years
- description
- Detection of Differences in TILs counts in LDy lesions categorized by their risk of malignant progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathological diagnosis of laryngeal dysplasia. * Age \>18 years and informed consent. Exclusion Criteria: * Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions. * Congenital or acquired immunodeficiency disorders. * Synchronous malignancies. * Immunosuppressive therapy. * Age \<18 years or absence of research consent.
References
Publications (0)
Data not yet available
No reference posted for this study.